GILD – gilead sciences, inc. (US:NASDAQ)

News

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy [Yahoo! Finance]
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question [Yahoo! Finance]
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion [Yahoo! Finance]
Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com